KR20230167025A - 4-1bb 및 ox40 결합 단백질을 포함하는 조성물 및 이의 용도 - Google Patents

4-1bb 및 ox40 결합 단백질을 포함하는 조성물 및 이의 용도 Download PDF

Info

Publication number
KR20230167025A
KR20230167025A KR1020237031740A KR20237031740A KR20230167025A KR 20230167025 A KR20230167025 A KR 20230167025A KR 1020237031740 A KR1020237031740 A KR 1020237031740A KR 20237031740 A KR20237031740 A KR 20237031740A KR 20230167025 A KR20230167025 A KR 20230167025A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
antigen
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237031740A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 레너드 비엔베뉴
Original Assignee
압테보 리서치 앤드 디벨롭먼트 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 압테보 리서치 앤드 디벨롭먼트 엘엘씨 filed Critical 압테보 리서치 앤드 디벨롭먼트 엘엘씨
Publication of KR20230167025A publication Critical patent/KR20230167025A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237031740A 2021-02-17 2022-02-17 4-1bb 및 ox40 결합 단백질을 포함하는 조성물 및 이의 용도 Pending KR20230167025A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150475P 2021-02-17 2021-02-17
US63/150,475 2021-02-17
PCT/US2022/016776 WO2022178114A1 (en) 2021-02-17 2022-02-17 Compositions comprising 4-1bb and ox40 binding proteins and methods of use

Publications (1)

Publication Number Publication Date
KR20230167025A true KR20230167025A (ko) 2023-12-07

Family

ID=80738990

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237031740A Pending KR20230167025A (ko) 2021-02-17 2022-02-17 4-1bb 및 ox40 결합 단백질을 포함하는 조성물 및 이의 용도

Country Status (8)

Country Link
US (1) US20240150483A1 (https=)
EP (1) EP4294843A1 (https=)
JP (1) JP2024508746A (https=)
KR (1) KR20230167025A (https=)
CN (1) CN117203236A (https=)
AU (1) AU2022223692A1 (https=)
CA (1) CA3208339A1 (https=)
WO (1) WO2022178114A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120584137A (zh) 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP1712240B1 (en) * 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
CN114181309B (zh) * 2015-05-21 2024-07-30 鳄鱼生物科学公司 新型多肽
MY197202A (en) * 2017-03-16 2023-05-31 Lg Chemical Ltd A liquid formulation of anti-tnf alpha antibody
ES3044118T3 (en) * 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
BR112021013571A2 (pt) * 2019-01-16 2021-09-21 Compass Therapeutics Llc Formulações de anticorpos que se ligam a cd137 humano e usos das mesmas
US20220242962A1 (en) * 2019-08-12 2022-08-04 Aptevo Research And Development Llc 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40

Also Published As

Publication number Publication date
JP2024508746A (ja) 2024-02-28
AU2022223692A1 (en) 2023-09-21
CN117203236A (zh) 2023-12-08
CA3208339A1 (en) 2022-08-25
WO2022178114A1 (en) 2022-08-25
EP4294843A1 (en) 2023-12-27
US20240150483A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
US11976133B2 (en) Bispecific T cell engagers
JP7515412B2 (ja) 新規のサイトカインプロドラッグ
CN109942712B (zh) 抗pd-l1/vegf双功能抗体及其用途
KR102742528B1 (ko) 항-bcma 중쇄-단독 항체
AU2022259766B2 (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
KR102259085B1 (ko) Edb 표적화 il-12 조성물
US20230192854A1 (en) Anti-btla antibody pharmaceutical composition and use thereof
KR102608723B1 (ko) 항―ｐｄ－１ 항체 및 그의 용도
US20220073616A1 (en) Methods of administering anti-tim-3 antibodies
US11680102B2 (en) Anti-BAFF receptor antibodies and uses thereof
KR20230110303A (ko) 폴레이트 수용체 알파에 결합하는 중쇄 항체
JP2022513350A (ja) がんの併用療法
KR20230167025A (ko) 4-1bb 및 ox40 결합 단백질을 포함하는 조성물 및 이의 용도
WO2024231251A1 (en) Anti-il1rap antibodies
KR20230050356A (ko) Pd-l1 및 tgf-베타를 표적화하는 이기능적 분자
US12486331B2 (en) Bispecific T cell engagers
WO2024165403A1 (en) Anti-cea antibodies
KR20250110243A (ko) 비호지킨 림프종 치료 방법
JP2025515325A (ja) 抗ｉｌｔ４抗体又はその抗原結合フラグメントの医薬製剤及び使用方法
EA053218B1 (ru) Антитела на основе тяжелых цепей, связывающиеся с альфа-рецептором фолата
TW202602924A (zh) 抗ccr8抗體之醫藥配製物
EP4185388A1 (en) A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230915

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250214

Comment text: Request for Examination of Application